Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study
|ClinicalTrials.gov Identifier: NCT01963130|
Recruitment Status : Completed
First Posted : October 16, 2013
Last Update Posted : October 16, 2013
|Condition or disease|
|Drug Mechanism Drug Usage|
|Study Type :||Observational|
|Actual Enrollment :||97 participants|
|Observational Model:||Case Control|
|Official Title:||Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
drug (metformin and gliclazide)
The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
drug (metformin, gliclazide and vildagliptin)
The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
- This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on portal hemodynamics. [ Time Frame: at least 3 month (mean 7.8 months) ]This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure in patients with type 2 diabetes mellitus. Portal vein flow velocity, portal vein flow, and portal vein diameter of all cases were measured by Doppler ultrasound in both groups.
- This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on hepatosteatosis. [ Time Frame: followed for at least 3 months (mean 7.8 months) ]Patients were examined in the left decubitus position with a Logiq 9 Review (GE, Milwaukee, WI, USA) ultrasound device and a 3.5-mHz convex transducer probe was used. Gray scale and color Doppler features were used. All segments of the liver were examined and the presence and degree of hepatosteatosis was recorded
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01963130
|Istanbul, Turkey, 34093|
|Study Director:||Cumali Karatoprak, MD||Bezmialem VU|